<p>The world is in desperate need of a COVID-19 cure. With more than two million people now infected with a record 129,045 deaths, we are running out of time. But we may also be one step closer to a solution with companies like Modern (NASDAQ: MRNA) and Inovio Pharmaceuticals (NASDAQ: INO) in human trials, but does that make the INO stock worth getting into now?
Source: Ascannio / Shutterstock.com
Modern is in a phase 1 study of its mRNA-1273 with the National Institute of Allergy and Infectious Diseases (NIAID). They have just started registering patients.
“Modern Covid-19 vaccine, which has attracted enormous attention in recent months, is among nine experimental prophylactic vaccines that the company is developing. All vaccines using the same approach, where small pieces of messenger RNA is used to activate the immune system against a particular virus, “reports Barron’s contributor Josh Nathan-Kazis.
At the same time, Inovio just launched its phase 1 studies with INO-4800 for a vaccine. If all goes according to plan, INO can run at at least $ 20 per share.
Human trials for INO-4800 Already started
Following approval by the US FDA in early April 2020, trials began on 40 adult volunteers in Philadelphia and Kansas City.
According to a statement from the company, “each participant will receive two doses of INO-4800 at four-week intervals, which should provide Inovio with initial immune responses and late summer safety data.”
“We have tested our DNA medicine vaccines with thousands of people during our experience. So we have a good grasp of how these vaccines react to the clinic, and we are very comfortable with that, says Inovio Senior Vice President, R&D, Kate Broderick. “We are very, very comfortable with the security database we have collected so far.”
The company has said that preclinical results for the vaccine were consistent with phase 1 studies of MERS, which was also caused by a coronavirus. If INO-4800 continues to show strong benefits, Inovio will quickly enter Phase 2. From there, if it succeeds, the company plans to have one million doses ready by the turn of the year.
Nothing is a guarantee for drug development, but there is good potential here that can drive the INO share higher through progression.
While a COVID-19 vaccine would really throw INO layers into the spotlight, it is not the only one in the Inovio pipeline.
Again, according to the website, the company uses DNA and the next generation sequencing and delivery to activate the immune system is also working on a variety of treatments.
For example, the company is currently in Phase 3 studies for cervical HSIL, or high-grade squamous intraepithelial lesions with VGX-3100., As well as treatments for vulvar HSIL and anal HSIL, which gave positive interim phase 2 results.
There are also Phase 1 studies for INO-3107 for recurrent respiratory papillomatosis (RRP), a rare disease that affects approximately 15,000 people in the United States each year.
In addition to the current Phase 2 studies of INO-5151 for prostate cancer, Phase 2 studies of MEDi0457 for the treatment of neck and head cancer and Phase 2 studies of INO-5401 for the treatment of glioblastoma, it is unfortunately a common brain tumor.
In short, Inovio has a pretty healthy pipeline. Although not yet profitable, it may soon change, as human trials of its COVID-19 vaccine continue. If all goes well, I strongly believe that the INO share could quickly rise to $ 20 per share in the short term.
Ian Cooper, a contributor to InvestorPlace.com, has been analyzing shares and options for web-based advisory services since 1999. At the time of writing, Ian Cooper had no position in any of the above securities.